Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
32.32
+0.85 (2.70%)
At close: May 8, 2026, 4:00 PM EDT
32.21
-0.11 (-0.34%)
After-hours: May 8, 2026, 7:59 PM EDT

Beam Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-65.98-79.99-376.74-132.53-289.09-370.64
Depreciation & Amortization
22.3722.2921.9320.0114.157.45
Stock-Based Compensation
86.6194.24120.6698.6584.3243.57
Other Adjustments
-12.27-250.63-2.87-18.87-38.48142.1
Changes in Accounts Payable
4.466.041.81-7.582.370.82
Changes in Accrued Expenses
9.897.69-57.6967.66-16.9343.91
Changes in Unearned Revenue
-134.3-135.42-36.52-159.56-35.92348.16
Changes in Other Operating Activities
-41.21-9.32-17.83-16.98302.11-281.63
Operating Cash Flow
-369.73-345.1-347.25-149.222.53-66.27
Capital Expenditures
-14.11-14.95-8.95-33.73-48.95-46.81
Purchases of Investments
-1,024-1,210-486.44-984.34-1,617-777.22
Proceeds from Sale of Investments
806.641,103680.391,0901,205529.27
Payments for Business Acquisitions
--0.08---0.62
Investing Cash Flow
28.92-121.44185.0171.84-461.34-294.14
Long-Term Debt Issued
93.89-----
Long-Term Debt Repaid
---0.49-2.25-2.29-2.12
Net Long-Term Debt Issued (Repaid)
93.89--0.49-2.25-2.29-2.12
Issuance of Common Stock
8.21478.058.22278.7114.07767.08
Net Common Stock Issued (Repurchased)
8.21478.058.22278.7114.07767.08
Other Financing Activities
-0.81----0.19-8.82
Financing Cash Flow
101.28478.057.74276.45111.59756.14
Net Cash Flow
-239.5311.51-154.5199.09-327.22395.73
Free Cash Flow
-383.84-360.05-356.19-182.93-26.42-113.08
FCF Margin
-234.04%-257.65%-560.77%-48.43%-43.37%-218.11%
Free Cash Flow Per Share
-3.72-3.64-4.33-2.37-0.38-1.76
Levered Free Cash Flow
-124.06-203.66-474.47-264.95-74.55-300.86
Unlevered Free Cash Flow
-524.53-507.36-512.77-304.82-117.22-320.57
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q